Umbilical cord blood concentration of connecting peptide (C-peptide) and pregnancy outcomes.

What Was Tested

Researchers studied C-Peptide in this randomized controlled trial publication.

Here the researchers sought to investigate the associations between fetomaternal metabolic variables and umbilical cord blood C-peptide concentration.

Why It Was Studied

C-peptide offers potential as a marker to indicate childhood metabolic outcomes.

Measuring C-peptide concentration might have better future utility in the risk stratification of neonates born to overweight or diabetic mothers.

Who Took Part

According to the abstract, 858 women were involved.

By PubMed's age tags, the people studied were children, women only.

How the Study Was Run

The design is described as randomized.

The women were allocated by chance, so the C-Peptide group and the comparison group should start out alike.

Their umbilical cord (UC) blood C-peptide concentrations were measured, and the pregnancy variables of macrosomia/large for gestational age (LGA) and primary cesarean section (CS) delivery were assessed.

The variation of C-peptide concentrations among GDM and macrosomia status was plotted.

Due to the skewed distribution of C-peptide concentration in the sample, median regression analysis was used to identify potential factors related to UC C-peptide concentration.

What Was Measured

C-peptide offers potential as a marker to indicate childhood metabolic outcomes.

Measuring C-peptide concentration might have better future utility in the risk stratification of neonates born to overweight or diabetic mothers.

Topics PubMed links to this paper include Birth Weight, Body Mass Index, C-Peptide, Cesarean Section, Diabetes, Gestational, Fetal Blood and Fetal Macrosomia.

The authors tagged it with the keywords Gestational diabetes mellitus and Pregnancy outcomes.

What This Means in Plain Language

The paper is a randomized study of C-Peptide in 858 women.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (BMC pregnancy and childbirth), a journal based in England.

More context: the C-Peptide compound page, all human trials.